Registration - In-house Corporation

Medicago Inc / Toshifumi Tada, President and Chief Executive Officer

Registration Information

In-house Corporation name: Medicago Inc
Responsible Officer Name: Toshifumi Tada, President and Chief Executive Officer
Responsible Officer Change History
Initial registration start date: 2021-11-15
Registration status: Inactive
Registration Number: 952231-370653

Associated Communications

Total Number of Communication Reports: 17

Monthly communication reports in the last 6 months: 0

Version 3 of 5 (2022-04-30 to 2022-05-01)

Registration versions:

Version 3 of 5 (2022-04-30 to 2022-05-01)

Lobbying Information

Subject Matters

Health
Science and Technology

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Obtain financial support from the Federal Government regarding research and development activities

Policies or Program

Advocacy to maintain and increase funding for the National Immunization Strategy.
Discussions on Canada’s procurement policies related to vaccines, in particular as it relates to Medicago’s COVID-19 vaccine candidate.
To actively promote the value of the pharmaceutical industry for Canada's economy, including through policies that will attract increased investment in the pharmaceutical industry.

Communication Techniques

Written communication
Oral communication
Grass-roots communication

Government Institutions

Canada Economic Development for Quebec Regions
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Prime Minister's Office (PMO)
Senate of Canada

In-house Corporation Details

Description of activities

Medicago is a pioneer and global leader in developing and producing plant-based vaccines and therapeutics. Medicago’s unique technology harnesses the natural processes of living plants to help respond to new global health challenges.

Responsible officer name and position during the period of this registration

Takashi Nagao, President and Chief Executive Officer

Government funding

End date of the last completed financial year: 2021-03-31

List of Government Funding
Government Institution	Funding Received in Last Financial Year	Funding Expected in Current Financial Year
Innovation, Science and Economic Development Canada (ISED)	$21,075,000.00	Yes
Investissement Quebec	$7,000,000.00	No
National Research Council (NRC)	$270,199.45	Yes

In-house Corporation Contact Information

Address:
1020 route de l'Eglise, Suite 600
Quebec, QC G1V 3V9
Canada

Telephone number: 418-658-9393

Parent Company Information

Mitsubishi Tanabe Pharma Corporation
- 2-10, Dosho-machi 3-chome, Chuo-ku
  Osaka 541-8505
  Japan

Subsidiary Beneficiary Information

Medicago R&D Inc
- 1020 route de l'Eglise, Suite 600
  Quebec, QC G1V 3V9
  Canada
Medicago USA
- 7 Triangle Drive
  Durham, NC 27713
  United States of America

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Takashi Nagao, President and Chief Executive Officer | No public offices held
Nicolas Petit, Vice President, Commercial Operations | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

No lobbyists added

Medicago Inc

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Medicago Inc	2021-11-15	2023-05-01

Medicago Inc

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Toshifumi Tada	2022-05-01	2023-05-01
Takashi Nagao	2021-11-15	2022-05-01

Date Modified:: 2025-03-07

Search and menus

Language selection

Registration - In-house Corporation

Medicago Inc / Toshifumi Tada, President and Chief Executive Officer

Registration Information

Associated Communications

Version 3 of 5 (2022-04-30 to 2022-05-01)

Version 3 of 5 (2022-04-30 to 2022-05-01)

Subject Matters

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Policies or Program

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties